Unmet needs in metastatic bone disease and its complications: Is progress possible?

Seminars in Oncology

Volumn 28, Issue 2 SUPPL. 6, 2001, Pages 1-3

  Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PAMIDRONIC ACID; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BONE DISEASE; BONE METASTASIS; BREAST CANCER; CLINICAL TRIAL; DRUG RESPONSE; HUMAN; MULTIPLE MYELOMA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0034990442     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.24153     Document Type: Review

References (12)

1. Multiple myeloma: Review of 869 cases
2. Metastases in carcinoma. Analysis of 1000 autopsied cases
3. The clinical course of bone metastases from breast cancer
4. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
5. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
6. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
7. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastasis in node-positive breast cancer patients: 5-year results of a randomized controlled trial
8. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer
9. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women
10. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer
11. Zoledronic acid reduces skeletal related events in patient with osteolytic metastases: A double-blind randomized dose-response study